None listed
Conditions
Brief summary
Radiotherapy treats cancer using high energy x-rays in order to destroy cancer cells including prostate cancer via a linear accelerator machine. A new technology, known as the SUPER-I is a prospective study that will assess the safety and efficacy of using the ‘SeedTracker’ system in prostate radiotherapy in South Western Sydney Local Health District. Who is it for? You may be eligible for this study if you are an adult male receiving radiotherapy treatment for prostate cancer within the Liverpool or Macarthur cancer therapy centres. Study details All participants in this study will undergo their usual radiotherapy treatment schedule. As part of this study, during the radiotherapy treatment, participants will have radiotherapy markers implanted in the prostate in order to detect the position of the prostate in real-time. All blood tests will be performed as standard care by your specialist. It is hoped that this study will improve radiotherapy treatment delivery accuracy for those with prostate cancer.
Interventions
SeedTracker is a real-time position monitoring tool, developed in South Western Sydney Local Health District (SWSLHD), which works in conjunction with the software system in Elekta Linear Accelerators. The majority of prostate cancer patients undergoing radiotherapy have the radiopaque markers implanted in the prostate for pre-treatment position verification. The SeedTracker system monitors the prostate position during the treatment delivery in real-time by detecting the position of the radiopaq
SeedTracker is a real-time position monitoring tool, developed in South Western Sydney Local Health District (SWSLHD), which works in conjunction with the software system in Elekta Linear Accelerators. The majority of prostate cancer patients undergoing radiotherapy have the radiopaque markers implanted in the prostate for pre-treatment position verification. The SeedTracker system monitors the prostate position during the treatment delivery in real-time by detecting the position of the radiopaque markers via monoscopic x-ray images acquired during treatment delivery. Treating Radiation Therapists will use the SeedTracker in conjunction with the Linear accelerators, with Physics support to monitor the patient during their treatment delivery. This will be delivered daily throughout the prescribed treatment course (20 or 39 days) at the participating hospitals. This study will assess the use of SeedTracker on patients receiving radiotherapy to the prostate in terms of safety and efficacy impacts to the department and patients through use of surveys and collated treatment delivery times. The study will also quantify prostate motion during treatment and corrections required for position deviations by recording daily data. The study will analyse collected data to provide insight on any additional workload or resources required for the implementation of real-time position monitoring in conventional prostate radiotherapy and improve radiotherapy treatment delivery accuracy.
Sponsors
Liverpool Hospital Cancer Therapy
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
Male
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Prostate cancer patients that receive radiotherapy treatment for prostate with current treatment protocol used within Liverpool and Macarthur cancer therapy centres. 2. Patients implanted with three prostate radio opaque markers 3. Patients receiving definitive radiotherapy to the prostate
Exclusion criteria
1. Patients with hip prosthesis
Outcome results
None listed